These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 26663410

  • 1. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M, investigators of the LEOPOLD Kids Trial.
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, Maas Enriquez M.
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
    Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M.
    Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S, Alamelu J, Ehrenforth S, Hanabusa H, Abdul Karim F, Kavakli K, Khodaie M, Staber J, Stasyshyn O, Yee DL, Rageliene L.
    Thromb Haemost; 2017 Aug 30; 117(9):1705-1713. PubMed ID: 28692108
    [Abstract] [Full Text] [Related]

  • 5. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
    Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulytė Trakymienė S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N.
    Thromb Res; 2020 May 30; 189():96-101. PubMed ID: 32197139
    [Abstract] [Full Text] [Related]

  • 6. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
    Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M.
    Haemophilia; 2020 May 30; 26(3):e55-e65. PubMed ID: 32212300
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA.
    J Thromb Haemost; 2017 Mar 30; 15(3):411-419. PubMed ID: 27992112
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J, Pathfinder™2 Investigators.
    Thromb Haemost; 2017 Jan 26; 117(2):252-261. PubMed ID: 27904904
    [Abstract] [Full Text] [Related]

  • 9. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES, Stasyshyn O, Alvarez-Román MT, Osman D, Liesner R, Engl W, Sharkhawy M, Abbuehl BE.
    Haemophilia; 2017 Mar 26; 23(2):238-246. PubMed ID: 27891721
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
    Yang R, Sun J, Zhao Y, Wang X, Wu D, Tseneklidou-Stoeter D, Wu J, Church N.
    Haemophilia; 2019 May 26; 25(3):e153-e158. PubMed ID: 30993836
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
    Powell J, Martinowitz U, Windyga J, Di Minno G, Hellmann A, Pabinger I, Maas Enriquez M, Schwartz L, Ingerslev J, LipLong Study Investigators.
    Thromb Haemost; 2012 Nov 26; 108(5):913-22. PubMed ID: 23014711
    [Abstract] [Full Text] [Related]

  • 12. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
    Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M, LEOPOLD II Study Investigators.
    J Thromb Haemost; 2015 Mar 26; 13(3):360-9. PubMed ID: 25546368
    [Abstract] [Full Text] [Related]

  • 13. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.
    J Thromb Haemost; 2015 Jun 26; 13(6):967-77. PubMed ID: 25912075
    [Abstract] [Full Text] [Related]

  • 14. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, Ewenstein BM, Oh M, Spotts G.
    Haemophilia; 2016 Jul 26; 22(4):514-20. PubMed ID: 26930418
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E, KOGENATE Bayer European PMS Study Group.
    Thromb Haemost; 2008 Jan 26; 99(1):52-8. PubMed ID: 18217134
    [Abstract] [Full Text] [Related]

  • 16. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A, Coyle T, Lalezari S, Fischer K, Kohlstaedde B, Delesen H, Radke S, Michaels LA.
    Haemophilia; 2018 Sep 26; 24(5):733-740. PubMed ID: 29963724
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y, Xiao J, Yang R, Wu R, Hu Y, Beckmann H, Wu J, Hou Q, Sun J.
    Pediatr Hematol Oncol; 2017 Apr 26; 34(3):138-148. PubMed ID: 28727494
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P, Mullins ES, Konkle BA, McGuinn C, Park YS, Stasyshyn O, Zulfikar B, Engl W, Tangada S.
    Haemophilia; 2020 Jul 26; 26(4):e168-e178. PubMed ID: 32597029
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ.
    Haemophilia; 2016 May 26; 22(3):374-80. PubMed ID: 26582282
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.
    Haemophilia; 2018 Nov 26; 24(6):e391-e394. PubMed ID: 30402994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.